Want to see HK:2160 full AI Analyst Report?
Top Page
MicroPort CardioFlow Medtech Corp.
(2160)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$1.50
▲(20.00% Upside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial quality—widening losses, negative free cash flow, and a sharp step-up in leverage that increases balance-sheet risk. Technicals are comparatively better, showing improving near-term momentum, but valuation remains constrained by loss-making results and no dividend support.
Positive Factors
Revenue Growth
Steady top-line expansion indicates continued demand for the company’s cardiovascular intervention products. Sustained growth can improve operating leverage over time, broaden hospital and distributor adoption, and provide a foundation for eventual profitability.
Negative Factors
Persistent Unprofitability
Revenue growth has not yet translated into sustainable earnings, and losses widened versus 2024. Continued unprofitability limits internally generated capital, increases dependence on financing, and raises execution risk as the company scales its commercial operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Steady top-line expansion indicates continued demand for the company’s cardiovascular intervention products. Sustained growth can improve operating leverage over time, broaden hospital and distributor adoption, and provide a foundation for eventual profitability.
Read all positive factors
MicroPort CardioFlow Medtech Corp. (2160) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.63B
Dividend YieldN/A
Average Volume (3M)919.96K
Price to Earnings (P/E)―
Beta (1Y)1.92
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees1,415
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.49
Shares Outstanding1,273,311,400
10 Day Avg. Volume580,360
30 Day Avg. Volume919,963
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.49
Price to Sales (P/S)6.71
P/FCF Ratio-10.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)HK$300.12M
MicroPort CardioFlow Medtech Corp. Business Overview & Revenue Model
Company Description
MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily...
How the Company Makes Money
The company primarily makes money by selling medical devices and procedure-related consumables used in cardiovascular interventions to healthcare providers (such as hospitals and distributors). Revenue is generally generated per unit sold (or per ...
MicroPort CardioFlow Medtech Corp. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 443.79M | 49.52M | 47.47M | 36.66M | 31.53M |
| Gross Profit | 288.34M | 34.41M | 32.46M | 23.68M | 18.64M |
| EBITDA | -111.57M | -15.52M | -54.51M | -50.81M | -27.32M |
| Net Income | -146.41M | -6.77M | -66.58M | -66.37M | -28.78M |
Balance Sheet | |||||
| Total Assets | 5.21B | 366.47M | 363.87M | 438.35M | 527.92M |
| Cash, Cash Equivalents and Short-Term Investments | 1.39B | 186.10M | 150.38M | 303.11M | 379.68M |
| Total Debt | 1.81B | 10.53M | 9.95M | 13.94M | 19.73M |
| Total Liabilities | 3.22B | 62.19M | 34.20M | 36.16M | 41.69M |
| Stockholders Equity | 1.99B | 299.56M | 329.67M | 402.20M | 486.23M |
Cash Flow | |||||
| Free Cash Flow | -297.74M | -36.99M | -33.53M | -33.83M | -42.39M |
| Operating Cash Flow | -25.82M | -15.29M | -29.22M | -26.66M | -25.36M |
| Investing Cash Flow | 404.12M | -109.36M | -84.16M | -26.26M | -68.69M |
| Financing Cash Flow | 44.33M | -7.71M | -3.62M | -19.93M | 349.61M |
MicroPort CardioFlow Medtech Corp. Technical Analysis
Negative
1.25
Price Trends
1.20
Positive
1.62
Negative
3.13
Negative
Market Momentum
0.02
Positive
49.97
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2160, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.31, above the 50-day MA of 1.20, and below the 200-day MA of 3.13, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 49.97 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2160.
MicroPort CardioFlow Medtech Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.56B | 12.60 | 13.24% | 2.35% | 16.15% | 31.89% | |
70 Outperform | HK$1.75B | 17.71 | 7.42% | ― | 59.30% | 131.03% | |
59 Neutral | HK$5.98B | 92.46 | 1.72% | ― | 0.75% | -20.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
45 Neutral | HK$11.65B | 31.24 | 6.07% | 0.06% | -3.62% | ― | |
45 Neutral | HK$538.03M | -0.98 | -28.24% | ― | -38.15% | 25.70% |
* Healthcare Sector Average
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-6.22
-82.93%
HK:0853
MicroPort Scientific
6.08
-8.33
-57.81%
HK:1302
LifeTech Scientific Corporation
1.39
-0.62
-30.75%
HK:1789
AK Medical Holdings Ltd.
5.02
-0.75
-13.04%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.22
-2.88
-70.24%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
45.18
-17.42
-27.83%
MicroPort CardioFlow Medtech Corp. Corporate Events
MicroPort CardioFlow Restructures Leadership and Board to Strengthen Governance
Aug 26, 2026
MicroPort CardioFlow Medtech Corp. has reshuffled its senior leadership and board roles, reassigning key executives while maintaining continuity in strategic oversight. The changes are effective August 26, 2026 and involve updates to the compositi...
MicroPort CardioFlow Sets Out Board Composition and Committee Roles
Aug 26, 2026
MicroPort CardioFlow Medtech Corp. has detailed the composition of its board of directors and clarified the roles held by each member, underscoring a governance framework that mixes executive, non-executive, and independent oversight. The board is...
MicroPort CardioFlow Delays Board Meeting to Complete Lease Evaluation for Interim Results
Aug 26, 2026
MicroPort CardioFlow Medtech Corporation has postponed its previously scheduled board meeting from August 26 to August 31, 2026, delaying consideration and approval of the group’s interim results for the six months ended June 30, 2026. The m...
MicroPort CardioFlow Medtech Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 14, 2026
MicroPort CardioFlow Medtech Corporation, a Cayman Islands-incorporated cardiovascular medical technology company listed in Hong Kong and operating from Shanghai, develops interventional devices and solutions targeting heart disease treatment in C...
MicroPort CardioFlow Signals Revenue Surge as CRM Acquisition Fuels Global Growth
Aug 11, 2026
MicroPort CardioFlow Medtech expects to report at least US$153 million in revenue and a net loss capped at US$25 million for the first half of 2026, reflecting the first full consolidation of its newly acquired cardiac rhythm management business. ...
MicroPort CardioFlow signs two major Shanghai production leases
Aug 2, 2026
MicroPort CardioFlow Medtech has entered into two five-year lease agreements in Shanghai through its subsidiaries MP CardioFlow and MicroPort CRM Shanghai, effective from August 1, 2026 to July 31, 2031. The first lease covers a 9,042.09 sq.m prop...
MicroPort CardioFlow Grants 440,000 Share Options Under 2023 Incentive Scheme
Jun 4, 2026
MicroPort CardioFlow Medtech Corp. has granted 440,000 share options to three group employees under its share scheme adopted in 2023, allowing each option holder to subscribe for one ordinary share at an exercise price of HK$1.678. The options, wh...
MicroPort CardioFlow Wins Shareholder Backing for AGM Resolutions and Capital Mandates
Jun 4, 2026
MicroPort CardioFlow Medtech Corp. reported that all resolutions at its annual general meeting on June 4, 2026, were duly approved by shareholders via poll, including the receipt of 2025 audited financial statements. Shareholders also renewed mand...
MicroPort CardioFlow Sets Board Lineup and Committee Structure
Jun 4, 2026
MicroPort CardioFlow Medtech Corp. has announced the composition of its board of directors, led by non-executive chairman Chen Guoming and co-chairman Brian Chang, alongside executive directors Zhang Ruinian, the chief executive officer, and presi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.